Intermittent androgen deprivation therapy in advanced prostate cancer

Current Treatment Options in Oncology

Volumn 15, Issue 1, 2014, Pages 127-136

  Alva, Ajjai ^b   Hussain, Maha ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b NONE

Author keywords

Androgen deprivation therapy; Continuous; Intermittent; Prostate cancer; SWOG 9346

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; DIETHYLSTILBESTROL; ENZALUTAMIDE; FLUTAMIDE; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE; ORTERONEL; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANDROGEN RELEASE; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; COMPARATIVE EFFECTIVENESS; DISEASE SPECIFIC SURVIVAL; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; METASTATIC PROSTATE CANCER; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PATIENT COUNSELING; PRIMARY HEALTH CARE; PROSTATE CANCER; SEXUAL FUNCTION; TREATMENT DURATION; TREATMENT RESPONSE;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; META-ANALYSIS AS TOPIC; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84894684822     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-013-0272-2     Document Type: Article

References (31)

1. National Cancer Institute: prostate cancer. http://www.cancer.gov/ cancertopics/types/prostate.
2. Ryan CJ et al. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol. 2006;24(5):396-402.
3. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6 Suppl 1):3-12.
4. http://seer.cancer.gov/statfacts/html/prost.html.
5. Riihimaki M et al. What do prostate cancer patients die of? Oncologist. 2011;16(2):175-81.
6. Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171(6 Pt 1):2285-90.
7. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, 1941. J Urol. 2002;168(1):9-12.
8. Alva A, Hussain M. Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer. Drugs. 2013.
9. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010;57(1):49-59.
10. Bruchovsky N et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990;50(8):2275-82.
11. Sato N et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol. 1996;58(2):139-46.
12. Klotz LH et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer. 1986;58(11):2546-50.
13. Lepor H, Shore ND. lhrh agonists for the treatment of prostate cancer: 2012. Rev Urol. 2012;14(1-2):1-12.
14. Shaw GL et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int. 2007;99(5):1056-65.
15. Hussain M et al. Intermittent vs continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368(14):1314-25. The largest randomized controlled trial and including only metastatic patients with prostate cancer.
16. Crook JM et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367(10):895-903. A large well designed randomized phase 3 trial on patients with biochemical relapse after radiation therapy to prostate.
17. Silva FC, et al. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Eur Urol. 2013.
18. Calais da Silva FE et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55(6):1269-77.
19. Mottet N et al. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int. 2012;110(9):1262-9.
20. Salonen AJ et al. The FinnProstate Study VII: intermittent vs continuous androgen deprivation in patients with advanced prostate cancer. J Urol. 2012;187(6):2074-81.
21. Miller K, Lingnau A, et al. Randomised prospective study of intermittent vs continuous androgen suppression in advanced prostate cancer. J Clin Oncol. 25:238 s, 207 (Supp) abstract 5015).
22. Langenhuijsen JF et al. Continuous vs intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol. 2013;31(5):549-56.
23. Schasfoort E, Heathcote P, Lock MTWT, et al. Intermittent androgen suppression with buserelin and nilutamide for the treatment of prostate cancer patients. European Urology Supplements, Volume 2, Issue 1, February 2003, Pages 187; XVIIIth Congress of the European Association of Urology. 2003.
24. Hussain M, Higano C, Crawford D, Liu G, Wilding G, Prescott S, et al. Intermittent (IAD) vs continuous androgen deprivation (CAD) in hormone sensitive metast atic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial. J Clin Oncol. 2012;30(suppl; abstract 4).
25. Hussain M et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24(24):3984-90.
26. Tsai HT et al. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology. 2013;82(2):327-33.
27. Sciarra A et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol. 2013;64(5):722-30.
28. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent vs continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol. 2013;31(16):2029-36. An excellent systematic review of intermittent and continuous ADT in advanced prostate cancer patients and including quality of life variables.
29. Keizman D et al. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate. 2011;71(15):1608-15.
30. Sciarra A et al. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery. Urol Oncol. 2013;31(5):607-14.
31. Yu EY et al. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol. 2010;28(16):2668-73.